Who are SOMATROPIN's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Skytrofa, Omnitrope, Omnitrope, NGENLA (Somatrogon), GH treatment (Genotropin), SKYTROFA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/somatropin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

SOMATROPIN — Competitive Intelligence Brief

SOMATROPIN (SOMATROPIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant Human Growth Hormone [EPC].

marketed Recombinant Human Growth Hormone [EPC] Recombinant protein Live · refreshed every 30 min

Target snapshot

SOMATROPIN (SOMATROPIN).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SOMATROPIN TARGET	SOMATROPIN		marketed	Recombinant Human Growth Hormone [EPC]		1976-01-01
Skytrofa	LONAPEGSOMATROPIN	Ascendis Pharma Encocrinology Div A/S	marketed	Recombinant Human Growth Hormone [EPC]	Growth hormone receptor	2021-01-01
Omnitrope	Somatropin	Serono	marketed	Recombinant human growth hormone	Dimeric GH receptors on cell membranes of target tissues	1976-01-01
Omnitrope	Somatropin	Serono	marketed	Recombinant human growth hormone	Dimeric GH receptors on cell membranes	1976-01-01
NGENLA (Somatrogon)	ngenla-somatrogon	Pfizer	marketed	Recombinant human growth hormone	Growth hormone receptor
GH treatment (Genotropin)	GH treatment (Genotropin)	Rabin Medical Center	marketed	Recombinant human growth hormone (somatropin)	Growth hormone receptor (GHR)
SKYTROFA	LONAPEGSOMATROPIN-TCGD	ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S	marketed	Recombinant Human Growth Hormone [EPC]	growth hormone (GH) receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant Human Growth Hormone [EPC] class)

· 1 drug in this class
ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S · 1 drug in this class
Ascendis Pharma Encocrinology Div A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SOMATROPIN — Competitive Intelligence Brief. https://druglandscape.com/ci/somatropin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab